{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:40:10Z","timestamp":1792150810776,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T00:00:00Z","timestamp":1305072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00105-010-2044-2","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T18:48:46Z","timestamp":1304966926000},"page":"430-435","source":"Crossref","is-referenced-by-count":3,"title":["Medikament\u00f6se Therapie nichtmelanozyt\u00e4rer epithelialer Tumore","Current therapy of non-melanoma skin cancer"],"prefix":"10.1007","volume":"62","author":[{"given":"M.","family":"Schlaak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"von Bartenwerffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,11]]},"reference":[{"key":"2044_CR1","unstructured":"Epidemiologisches Krebsregister Nordrhein Westfalen. http:\/\/www.krebsregister.nrw.de"},{"key":"2044_CR2","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/sj.jid.5700895","volume":"127","author":"Stang","year":"2007","unstructured":"Stang A (2007) Genital and nongenital nonmelanoma skin cancer: more epidemiological studies are needed. J Invest Dermatol 127(10):2296\u20132299","journal-title":"J Invest Dermatol"},{"key":"2044_CR3","doi-asserted-by":"crossref","unstructured":"Crowson AN (2006) Basal cell carcinoma: biology, morphology and clinical implications. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. [Research Support, Non-U.S. Gov\u2019t Review] 19(Suppl 2):S127\u2013S147","DOI":"10.1038\/modpathol.3800512"},{"key":"2044_CR4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/287795a0","volume":"287","author":"Nusslein-Volhard","year":"1980","unstructured":"Nusslein-Volhard C, Wieschaus E (1980) Mutations affecting segment number and polarity in Drosophila. Nature 287(5785):795\u2013801","journal-title":"Nature"},{"key":"2044_CR5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nrg1969","volume":"7","author":"Ingham","year":"2006","unstructured":"Ingham PW, Placzek M (2006) Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 7(11):841\u2013850","journal-title":"Nat Rev Genet"},{"key":"2044_CR6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrc1652","volume":"5","author":"Cleaver","year":"2005","unstructured":"Cleaver JE (2005) Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Genet 5(7):564\u2013573","journal-title":"Nat Rev Genet"},{"key":"2044_CR7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1610-0387.2007.06318.x","volume":"5","author":"Peris","year":"2007","unstructured":"Peris K, Micantonio T, Piccolo D, Fargnoli MC (2007) Dermoscopic features of actinic keratosis. JDDG 5(11):970\u2013976","journal-title":"JDDG"},{"key":"2044_CR8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2008.01.009","volume":"261","author":"Oberyszyn","year":"2008","unstructured":"Oberyszyn TM (2008) Non-melanoma skin cancer: importance of gender, immunosuppressive status and vitamin D. Cancer Lett 261(2):127\u2013136","journal-title":"Cancer Lett"},{"key":"2044_CR9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2340\/00015555-0919","volume":"90","author":"Jensen","year":"2010","unstructured":"Jensen AO, Svaerke C, Farkas D et al (2010) Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol 90(5):474\u2013479","journal-title":"Acta Derm Venereol"},{"key":"2044_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2004.11.011","volume":"56","author":"Gerlini","year":"2005","unstructured":"Gerlini G, Romagnoli P, Pimpinelli N (2005) Skin cancer and immunosuppression. Crit Rev Oncol Hematol 56(1):127\u2013136","journal-title":"Crit Rev Oncol Hematol"},{"key":"2044_CR11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","volume":"9","author":"Brantsch","year":"2008","unstructured":"Brantsch KD, Meisner C, Schonfisch B et al (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9(8):713\u2013720","journal-title":"Lancet Oncol"},{"key":"2044_CR12","first-page":"1125","volume":"9","author":"Goldberg","year":"2010","unstructured":"Goldberg LH, Mamelak AJ (2010) Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol 9(9):1125\u20131132","journal-title":"J Drugs Dermatol"},{"key":"2044_CR13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2133.2009.09453.x","volume":"161","author":"Ulrich","year":"2009","unstructured":"Ulrich C, Jurgensen JS, Degen A et al (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3):78\u201384","journal-title":"Br J Dermatol"},{"key":"2044_CR14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1365-2133.2010.09659.x","volume":"162","author":"Moloney","year":"2010","unstructured":"Moloney F, Vestergaard M, Radojkovic B, Damian D (2010) Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol 162(5):1138\u20131139","journal-title":"Br J Dermatol"},{"key":"2044_CR15","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/bjc.2011.95","volume":"104","author":"Reuschenbach","year":"2011","unstructured":"Reuschenbach M, Tran T, Faulstich F et al (2011) High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer 104(8):1334\u20131341","journal-title":"Br J Cancer"},{"key":"2044_CR16","first-page":"753","volume":"9","author":"Marquez","year":"2010","unstructured":"Marquez C, Bair SM, Smithberger E et al (2010) Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol 9(7):753\u2013758","journal-title":"J Drugs Dermatol"},{"key":"2044_CR17","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1524-4725.2010.01576.x","volume":"36","author":"Pugliano-Mauro","year":"2010","unstructured":"Pugliano-Mauro M, Goldman G (2010) Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 36(10):1544\u20131553","journal-title":"Dermatol Surg"},{"key":"2044_CR18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/jir.1995.15.537","volume":"15","author":"Gibson","year":"1995","unstructured":"Gibson SJ, Imbertson LM, Wagner TL et al (1995) Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15(6):537\u2013545","journal-title":"J Interferon Cytokine Res"},{"key":"2044_CR19","doi-asserted-by":"crossref","first-page":"571734","DOI":"10.1155\/2011\/571734","volume":"2011","author":"Lien","year":"2011","unstructured":"Lien MH, Sondak VK (2011) Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer 2011:571734","journal-title":"J Skin Cancer"},{"key":"2044_CR20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","volume":"50","author":"Geisse","year":"2004","unstructured":"Geisse J, Caro I, Lindholm J et al (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50(5):722\u2013733","journal-title":"J Am Acad Dermatol"},{"key":"2044_CR21","first-page":"677","volume":"18","author":"Gollnick","year":"2008","unstructured":"Gollnick H, Barona CG, Frank RG et al (2008) Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 18(6):677\u2013682","journal-title":"Eur J Dermatol"},{"key":"2044_CR22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/14656566.2011.549128","volume":"12","author":"Quist","year":"2011","unstructured":"Quist SR, Gollnick HP (2011) Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. Exp Opin Pharmacother 12(3):451\u2013461","journal-title":"Exp Opin Pharmacother"},{"key":"2044_CR23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1445-2197.1991.tb00230.x","volume":"61","author":"Daniell","year":"1991","unstructured":"Daniell MD, Hill JS (1991) A history of photodynamic therapy. Aust N Z J Surg 61(5):340\u2013348","journal-title":"Aust N Z J Surg"},{"key":"2044_CR24","first-page":"319","volume":"137","author":"Morton","year":"2001","unstructured":"Morton CA, Whitehurst C, McColl JH et al (2001) Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 137(3):319\u2013324","journal-title":"Arch Dermatol"},{"key":"2044_CR25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2133.2010.10098.x","volume":"164","author":"Serra-Guillen","year":"2011","unstructured":"Serra-Guillen C, Nagore E, Hueso L et al (2011) A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. Br J Dermatol 164(2):429\u2013433","journal-title":"Br J Dermatol"},{"key":"2044_CR26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1610-0387.2009.07293_supp.x","volume":"8","author":"Schlaak","year":"2010","unstructured":"Schlaak M, Simon JC (2010) Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid \u2013 pilot study. JDDG 8(3):174\u2013178","journal-title":"JDDG"},{"key":"2044_CR27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1440-0960.2010.00626.x","volume":"51","author":"Siller","year":"2010","unstructured":"Siller G, Rosen R, Freeman M et al (2010) PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Aust J Dermatol 51(2):99\u2013105","journal-title":"Aust J Dermatol"},{"key":"2044_CR28","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","volume":"361","author":"Von","year":"2009","unstructured":"Von Hoff DD, LoRusso PM, Rudin CM et al (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12):1164\u20131172","journal-title":"N Engl J Med"},{"key":"2044_CR29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","volume":"361","author":"Rudin","year":"2009","unstructured":"Rudin CM, Hann CL, Laterra J et al (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361(12):1173\u20131178","journal-title":"N Engl J Med"},{"key":"2044_CR30","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-10-2745","volume":"17","author":"Lorusso","year":"2011","unstructured":"Lorusso PM, Rudin CM, Reddy JC et al (2011) Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Clin Cancer Res 17(8):2512\u20132520","journal-title":"Clin Cancer Res"},{"key":"2044_CR31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1126\/science.276.5313.817","volume":"276","author":"Oro","year":"1997","unstructured":"Oro AE, Higgins KM, Hu Z et al (1997) Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 276(5313):817\u2013821","journal-title":"Science"},{"key":"2044_CR32","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/jnci\/djq442","volume":"102","author":"Elmets","year":"2010","unstructured":"Elmets CA, Viner JL, Pentland AP et al (2010) Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102(24):1835\u20131844","journal-title":"J Natl Cancer Inst"},{"key":"2044_CR33","doi-asserted-by":"crossref","first-page":"874571","DOI":"10.1155\/2011\/874571","volume":"2011","author":"Bito","year":"2011","unstructured":"Bito T, Sumita N, Ashida M et al (2011) Inhibition of epidermal growth factor receptor and PI3\u00a0K\/Akt signaling suppresses cell proliferation and survival through regulation of stat3 activation in human cutaneous squamous cell carcinoma. J Skin Cancer 2011:874571","journal-title":"J Skin Cancer"},{"key":"2044_CR34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/jid.2009.312","volume":"130","author":"Ridd","year":"2010","unstructured":"Ridd K, Bastian BC (2010) Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma. J Invest Dermatol 130(3):901\u2013903","journal-title":"J Invest Dermatol"},{"key":"2044_CR35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2006.07603.x","volume":"156","author":"Fogarty","year":"2007","unstructured":"Fogarty GB, Conus NM, Chu J, McArthur G (2007) Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 156(1):92\u201398","journal-title":"Br J Dermatol"},{"key":"2044_CR36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0625.2009.01028.x","volume":"19","author":"Toll","year":"2010","unstructured":"Toll A, Salgado R, Yebenes M et al (2010) Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol 19(2):151\u2013153","journal-title":"Exp Dermatol"},{"key":"2044_CR37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/DAD.0b013e318159bf95","volume":"29","author":"Schlauder","year":"2007","unstructured":"Schlauder SM, Calder KB, Moody P, Morgan MB (2007) HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma. Am J Dermatopathol 29(6):559\u2013563","journal-title":"Am J Dermatopathol"},{"key":"2044_CR38","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1634\/theoncologist.2009-0210","volume":"15","author":"Cranmer","year":"2010","unstructured":"Cranmer LD, Engelhardt C, Morgan SS (2010) Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist 15(12):1320\u20131328","journal-title":"Oncologist"},{"key":"2044_CR39","doi-asserted-by":"crossref","unstructured":"Maubec E, Duvillard P, Laouenan C et al (2010) Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28(15_suppl, May 20 Supplement):8510","DOI":"10.1200\/jco.2010.28.15_suppl.8510"},{"key":"2044_CR40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archderm.143.7.889","volume":"143","author":"Bauman","year":"2007","unstructured":"Bauman JE, Eaton KD, Martins RG (2007) Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 143(7):889\u2013892","journal-title":"Arch Dermatol"},{"key":"2044_CR41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/CAD.0b013e32809ef9e0","volume":"18","author":"Suen","year":"2007","unstructured":"Suen JK, Bressler L, Shord SS et al (2007) Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anti Cancer Drugs 18(7):827\u2013829","journal-title":"Anti Cancer Drugs"},{"key":"2044_CR42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1610-0387.2008.06861.x","volume":"6","author":"Jalili","year":"2008","unstructured":"Jalili A, Pinc A, Pieczkowski F et al (2008) Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. JDDG 6(12):1066\u20131069","journal-title":"JDDG"},{"key":"2044_CR43","doi-asserted-by":"crossref","unstructured":"Weinberg RA (2006) The biology of cancer. Garland Science","DOI":"10.1201\/9780203852569"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-010-2044-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-010-2044-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-010-2044-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:48:26Z","timestamp":1637624906000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-010-2044-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1007\/s00105-010-2044-2","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,11]]}}}